Cerity Partners LLC Buys New Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Cerity Partners LLC acquired a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 517,581 shares of the company's stock, valued at approximately $1,661,000. Cerity Partners LLC owned approximately 0.31% of Allogene Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Aaron Wealth Advisors LLC bought a new stake in shares of Allogene Therapeutics in the 4th quarter worth $34,000. Arizona State Retirement System increased its holdings in shares of Allogene Therapeutics by 22.2% in the 4th quarter. Arizona State Retirement System now owns 30,458 shares of the company's stock worth $98,000 after purchasing an additional 5,543 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Allogene Therapeutics by 353.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,467 shares of the company's stock worth $62,000 after purchasing an additional 15,170 shares in the last quarter. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Allogene Therapeutics in the 4th quarter worth $27,000. Finally, SG Americas Securities LLC bought a new stake in shares of Allogene Therapeutics in the 4th quarter worth $172,000. Institutional investors own 83.63% of the company's stock.

Analysts Set New Price Targets

ALLO has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Tuesday, March 19th. JMP Securities reaffirmed a "market perform" rating on shares of Allogene Therapeutics in a report on Friday, January 5th. Guggenheim lowered Allogene Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, January 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 15th. Finally, JPMorgan Chase & Co. cut their price objective on Allogene Therapeutics from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Tuesday, February 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $12.94.

Allogene Therapeutics Trading Up 0.3 %

NASDAQ ALLO traded up $0.01 on Friday, hitting $3.47. 2,013,218 shares of the company traded hands, compared to its average volume of 1,533,953. The company has a market capitalization of $586.74 million, a price-to-earnings ratio of -1.66 and a beta of 0.81. The business's 50 day moving average price is $4.49 and its 200-day moving average price is $3.54. Allogene Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its earnings results on Thursday, March 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.04. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.69 earnings per share for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).